SHANGHAI, Nov. 7, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2011 on November 21, 2011. Management will host a conference call to discuss the results at 8:00AM New York Time on November 21, 2011 (9:00PM Beijing time on November 21, 2011).

Conference Call

Mr. Michael Xin Hui, founder and Chief Executive Officer, Mr. Kevin Chen, President and Chief Operating Officer, Mr. William Dai, Chief Financial Officer, and Ms. Lan Xie, Vice President of Finance and Investor Relations, will discuss the results and take questions following the prepared remarks.

Dial-in details for the live conference call are as follows: 


    International:                        +1-718-354-1231

    United States:                        +1-866-519-4004
    United Kingdom:                       +080-8234-6646
    Hong Kong:                            +852-2475-0994

    Passcode:                             SHP

A live webcast of the conference call will be available on the investor relations section of the Company's website at: http://www.shangpharma.com.

A telephone replay of the call will be available for seven days from November 21, 2011, 11:00 AM ET to November 28, 2011, 11:59 PM ET. The dial-in details for the replay are as follows: 


    International:                        +61-2-8235-5000

    Passcode:                                                        25392229

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com. 


    For further information, please contact:

    ShangPharma
    Ms. Lan Xie
    VP of Finance and Investor Relations
    Email: ir@shangpharma.com

    Brunswick Group
    Josh Gartner
    Email: shangpharma@brunswickgroup.com
    Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation